A team of researchers sought to determine the efficacy of psilocybin as an antidepressant compared with placebo or ...

Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with ...

Good morning. My name is Madison, and I will be your conference operator today. At this time, I would like to welcome ...

What is extraordinary about tianeptine is its putative mechanism of action. It is a selective serotonergic reuptake enhancer. By having the exact opposite neurochemical effect as the most widely ...

If serotonergic drugs really did affect serotonin overall, they would cause absolutely horrible GI side effects, since the gut has considerably more serotonin and serotonergic neurons than the ...

As spring starts to show its true colors, people are running outside to start work in their gardens. I am one of those people ...

Current research in the lab is focused on using a recently developed temporally controlled genetic targeting approach to investigate the requirement for ongoing serotonergic transcription in serotonin ...

Consider using an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6. Discontinue Vyvanse and any concomitant drugs immediately if serotonin syndrome occurs ...

A review in Current Research in Food Science explores how bioactive compounds in coffee, tea, and cocoa combat obesity by ...

Q1 2024 Earnings Call Transcript April 30, 2024 Harmony Biosciences Holdings, Inc. beats earnings expectations. Reported EPS ...

Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with ...

Discover key financial outcomes and strategic insights from Harmony Biosciences' Q1 2024 earnings call, including robust revenue growth and promising clinical advancements.